Chardan Capital Forecasts Strong Price Appreciation for Avidity Biosciences (NASDAQ:RNA) Stock
Avidity Biosciences (NASDAQ:RNA – Get Free Report) had its price objective raised by research analysts at Chardan Capital from $65.00 to $75.00 in a report released on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s price target would indicate a potential upside of 123.08% from the company’s […]
Avidity Biosciences (NASDAQ:RNA – Get Free Report) had its price objective raised by research analysts at Chardan Capital from $65.00 to $75.00 in a report released on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s price target would indicate a potential upside of 123.08% from the company’s […]
